The trial did not meet its primary endpoint, a joint rank analysis of function and survival, and no efficacy was seen in the individual components of function or survival.

FORBES: Biogen Idec ALS Drug Fails

The analysis of overall survival (OS), a key secondary endpoint of the study, is event driven.

FORBES: Modified Cold Sore Virus Shrinks Melanoma Tumors, Amgen Says